Draper Develops Artificial Lung Technology with $4 9M U S Army Grant, Earns ASAIO Award prweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prweb.com Daily Mail and Mail on Sunday newspapers.
Share this article
Share this article
MONMOUTH JUNCTION, N.J., May 11, 2021 /PRNewswire/ CytoSorbents Corporation (NASDAQ: CTSO), a critical care leader commercializing its CytoSorb® and other blood purification technologies to treat deadly conditions in critically-ill and cardiac surgery patients around the world, announced the U.S Army Medical Research and Development Command has awarded CytoSorbents a Defense Health Agency (DHA) Sequential Phase II Small Business Innovation Research (SBIR) contract, valued at $1,499,987 over 28 months, to advance development of the K
+ontrol™ platform for the treatment of severe hyperkalemia induced by traumatic injury and acute kidney injury in austere medicine. This follows the successful completion of the previously announced Phase I and Phase II SBIR programs for this application, totaling approximately $1.15 million in previous contract funding.
3 FORT DETRICK, Md. In order to bolster the current fight against the global pandemic, U.S. Army Medical Logistics Command has spent the last several months tailoring packages of essential COVID-19 supplies.
This initiative has been executed utilizing multiple procurement options in collaboration with both the Defense Logistics Agency-Troop Support and the U.S. Army Medical Research Acquisition Activity.
In a Dec. 11 meeting with Army Materiel Command leaders, AMLC Commander Brig. Gen. Michael Lalor said the teams have worked together to ensure unit deployment packages, or UDPs, are filled and configured to go should the Army need to deploy additional military medical resources to support the whole-of-government response to COVID-19.